• The conference was organised by the UAI (Innovation Support Unit) of the IiSGM (Gregorio Marañón Health Research Institute) and was sponsored by GENESIS Biomed, HOFFMANN EITLE, DINAMIZA Health Research Accelerator and the support of the ITEMAS Platform.

• The conference brought together more than 400 attendees, consolidating its position as the annual benchmark event in Healthcare Entrepreneurship and Innovation in the Community of Madrid.

• The meeting addressed key challenges for healthcare spin-offs/startups, with a special focus on the regulatory path to the market, clinical evidence and regulation applicable to Artificial Intelligence-based solutions

On 23 February 2026, the Hospital General Universitario Gregorio Marañón hosted the IV Conference on Healthcare Entrepreneurship, held in the Assembly Hall of the hospital in Madrid.

The conference was organised by the UAI (Innovation Support Unit) of the IiSGM and was sponsored by GENESIS Biomed, HOFFMANN EITLE and DINAMIZA Acceleradora de la Investigación en Salud, with the support of the ITEMAS Platform.

GENESIS Biomed thus reaffirms its commitment to promoting biomedical entrepreneurship and technology transfer from the hospital environment to the market. This event has established itself as a benchmark event in the healthcare innovation ecosystem of the Community of Madrid, bringing together researchers, innovation managers, institutional representatives, investors and spin-offs/startups in the healthcare field. The event brought together more than 400 attendees, reflecting the dynamism of the sector and the interest it arouses.

After the institutional opening, with the intervention of the General Director of Research and Teaching of the Regional Ministry of Health of the Community of Madrid, Dr. Inmaculada Ibáñez, the day was structured around three round tables aimed at addressing, from a practical perspective, the main milestones that spinoffs/startups must face in their journey towards the market and regulatory compliance in Europe.

Our CEO, Josep Lluís Falcó, participated as moderator in the round table entitled “From prototype to market. Essential milestones to achieve CE Marking”, focusing on the critical steps to advance from initial technical validation to commercialisation, targeting the planning of the regulatory process and the importance of anticipating key requirements for obtaining CE Marking. During the event, it became clear that the proper structuring of the roadmap from the early stages contributes decisively to reducing risks and accelerating market access.

A second panel discussed the role of clinical evidence in health technology spinoffs/startups and its relevance to meet regulatory expectations and demonstrate value in the European environment and the third focused on the regulation associated with Artificial Intelligence solutions applied to health, putting on the table the challenges of compliance and the implications for the development and market launch of this type of technology.

Josep Lluís Falcó, CEO of GENESIS Biomed, stressed that “the success of a healthcare spinoff does not depend solely on scientific or technological excellence, but on the ability to correctly structure its regulatory, clinical and financial strategy from the outset. Comprehensive planning is what turns a promising development into a real market opportunity“.

The conference concluded with a catering and networking space that facilitated direct exchange between entrepreneurs, experts, institutions and support entities, reinforcing synergies within the healthcare innovation ecosystem.

The holding of this IV Conference confirms the growing interest in healthcare entrepreneurship and highlights the need to continue generating specialised forums where the challenges that determine the viability and growth of spin-offs in healthcare are addressed with rigour and strategic vision.